In early 2019, a South Korean company received the rights to use the Allostatin® molecule to treat certain types of cancer. By October, pilot studies on the use of injected Allostatin® in combined therapy for pancreatic cancer had been completed, these demonstrated the high effectiveness of the new treatment regimen.
U.S. Patent «Synergistic combination of chemotherapy and peptide for treating cancer» Pending.